INVOKANA®: a convenient once-daily oral tablet1

100 mg

For patients starting on INVOKANA®1

  • The recommended starting dose
  • Approved for use in patients with an eGFR ≥45 mL/min/1.73 m2

300 mg

For additional control1

  • For additional glycemic control in patients tolerating the 100-mg dose
  • Approved for use in patients with an eGFR ≥60 mL/min/1.73 m2

INVOKANA® 300 mg when taken before a mixed meal1*:

  • Delayed intestinal glucose absorption and reduced postprandial glucose excursion

*In single-dose pharmacokinetic/pharmacodynamic studies in healthy people and in patients with type 2 diabetes.

-Assess renal function before initiating INVOKANA® and periodically thereafter.

-In patients with volume depletion not previously treated with canagliflozin, normalize volume status before initiating INVOKANA®.

For more information on dosing and administration, please refer to the full Prescribing Information and Medication Guide.

Reference: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.